Literature DB >> 3557729

Aminoglycoside redistribution phenomenon after hemodialysis: netilmicin and tobramycin.

C E Halstenson, R O Berkseth, H J Mann, G R Matzke.   

Abstract

The serum concentration time profile of netilmicin and tobramycin before, during, and after hemodialysis was assessed in 5 noninfected adult chronic hemodialysis patients. The pharmacokinetic profile was biexponential for both agents in the pre-hemodialysis period. The total body clearance of netilmicin was significantly greater than that of tobramycin (5.32 +/- 0.75 ml/min vs 3.66 +/- 1.00 ml/min; p less than 0.05). The hemodialysis clearances of netilmicin and tobramycin were similar (60.8 +/- 16.6 ml/min and 54.7 +/- 18.8 ml/min, respectively). Netilmicin and tobramycin serum concentrations increased significantly 10 minutes after cessation of hemodialysis and maximally rebounded to 38.3 +/- 16.2% and 18.3 +/- 3.0% at 1.7 +/- 0.3 hours and 1.9 +/- 0.7 hours, respectively. This phenomenon may be a primary contributor to the marked variability observed in the clinical pharmacokinetics of these agents in hemodialysis patients. These data suggest that clinical serum concentrations should not be drawn until two hours after hemodialysis.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3557729

Source DB:  PubMed          Journal:  Int J Clin Pharmacol Ther Toxicol        ISSN: 0174-4879


  6 in total

Review 1.  Principles of drug administration in renal insufficiency.

Authors:  Y W Lam; S Banerji; C Hatfield; R L Talbert
Journal:  Clin Pharmacokinet       Date:  1997-01       Impact factor: 6.447

Review 2.  Clinical pharmacokinetics of antibiotics in patients with impaired renal function.

Authors:  W L St Peter; K A Redic-Kill; C E Halstenson
Journal:  Clin Pharmacokinet       Date:  1992-03       Impact factor: 6.447

Review 3.  Nonparametric meta-analysis of published data on kidney-function dependence of pharmacokinetic parameters for the aminoglycoside netilmicin.

Authors:  F Keller; K Erdmann; M Giehl; P Buettner
Journal:  Clin Pharmacokinet       Date:  1993-07       Impact factor: 6.447

4.  Isepamicin disposition in subjects with various degrees of renal function.

Authors:  C E Halstenson; J S Kelloway; M B Affrime; C C Lin; M A Teal; B E Shapiro; W M Awni
Journal:  Antimicrob Agents Chemother       Date:  1991-11       Impact factor: 5.191

5.  Influence of hemodialysis on gentamicin pharmacokinetics, removal during hemodialysis, and recommended dosing.

Authors:  Kevin M Sowinski; Stephanie J Magner; Aroonrut Lucksiri; Meri K Scott; Richard J Hamburger; Bruce A Mueller
Journal:  Clin J Am Soc Nephrol       Date:  2008-01-30       Impact factor: 8.237

Review 6.  Netilmicin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  D M Campoli-Richards; S Chaplin; R H Sayce; K L Goa
Journal:  Drugs       Date:  1989-11       Impact factor: 9.546

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.